Multi-drug management after myocardial infarction

被引:0
作者
Kritz, H
Sinzinger, H
机构
[1] WILHELM AUERSWALD ATHEROSKLEROSEFORSCH GRP ASF WI, A-1090 VIENNA, AUSTRIA
[2] UNIV VIENNA, KLIN NUKL MED, VIENNA, AUSTRIA
[3] REHABIL ZENTRUM ENGELSBAD, BADEN BEI WIEN, AUSTRIA
关键词
myocardial infarction; therapeutical intervention; thrombolysis;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Since the results of studies done with angiotensin-converting-enzyme(ACE)-inhibitors, systemic thrombolysis and primary percutaneous transluminal angioplasty (PTCA) have been published, post-myocardial infarction therapy has changed dramatically. In most european countries systemic thrombolysis as early as possible is the standard therapy. Cardiologists prefer more and more immediate revascularisation if the technical standard of the hospital is allowing an acute intervention. Pharmacological therapy is done initially with beta-blockers and platelet aggregation inhibitors, if necessary intravenously, since the results of the e. g. GUSTO-and the AIRE-study are known, If left ventricular dysfunction exists or develops, ACE-inhibitors are given after the third day post myocardial infarction.
引用
收藏
页码:17 / 24
页数:8
相关论文
共 73 条
[1]   LONG-TERM TREATMENT WITH BETA-BLOCKERS AFTER MYOCARDIAL-INFARCTION [J].
AHLMARK, G ;
SAETRE, H .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1976, 10 (02) :77-83
[2]  
*AIRE, 1993, LANCET, V341, P821
[3]  
[Anonymous], 1988, LANCET, V1, P921
[4]  
[Anonymous], 1988, LANCET, V2, P349
[5]  
[Anonymous], 1986, LANCET, V2, P57
[6]   INDICATIONS FOR FIBRINOLYTIC THERAPY IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - COLLABORATIVE OVERVIEW OF EARLY MORTALITY AND MAJOR MORBIDITY RESULTS FROM ALL RANDOMIZED TRIALS OF MORE THAN 1000 PATIENTS [J].
APPLEBY, P ;
BAIGENT, C ;
COLLINS, R ;
FLATHER, M ;
PARISH, S ;
PETO, R ;
BELL, P ;
HALLS, H ;
MEAD, G ;
DIAZ, R ;
PAOLASSO, E ;
PAVIOTTI, C ;
ROMERO, G ;
CAMPBELL, T ;
OROURKE, MF ;
THOMPSON, P ;
LESAFFRE, E ;
VANDEWERF, F ;
VERSTRAETE, M ;
ARMSTRONG, PW ;
CAIRNS, JA ;
MORAN, C ;
TURPIE, AG ;
YUSUF, S ;
GRANDE, P ;
HEIKKILA, J ;
KALA, R ;
BASSAND, JP ;
BOISSEL, JP ;
BROCHIER, M ;
LEIZOROVICZ, A ;
BRUGGEMANN, T ;
KARSCH, KR ;
KASPER, W ;
LAMMERTS, D ;
NEUHAUS, KL ;
MEYER, J ;
SCHRODER, R ;
VONESSEN, R ;
SARAN, RK ;
ARDISSINO, D ;
BONADUCE, D ;
BRUNELLI, C ;
CERNIGLIARO, C ;
FORESTI, A ;
FRANZOSI, MG ;
GUIDUCCI, D ;
MAGGIONI, A ;
MAGNANI, B ;
MATTIOLI, G .
LANCET, 1994, 343 (8893) :311-322
[8]  
*BET BLOCK HEART A, 1981, JAMA-J AM MED ASSOC, V247, P1707
[9]  
BROWN TM, 1985, CIRCULATION, V72, P309
[10]   A PILOT TRIAL OF RECOMBINANT DESULFATOHIRUDIN COMPARED WITH HEPARIN IN CONJUNCTION WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND ASPIRIN FOR ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI)-5 TRIAL [J].
CANNON, CP ;
MCCABE, CH ;
HENRY, TD ;
SCHWEIGER, MJ ;
GIBSON, RS ;
MUELLER, HS ;
BECKER, RC ;
KLEIMAN, NS ;
HAUGLAND, JM ;
ANDERSON, JL ;
SHARAF, BL ;
EDWARDS, SJ ;
ROGERS, WJ ;
WILLIAMS, DO ;
BRAUNWALD, E .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 23 (05) :993-1003